Ascendis Pharma (ASND)
(Delayed Data from NSDQ)
$140.80 USD
+3.76 (2.74%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $140.63 -0.17 (-0.12%) 6:20 PM ET
4-Sell of 5 4
F Value C Growth B Momentum F VGM
Brokerage Reports
Ascendis Pharma A/S [ASND/]
Reports for Purchase
Showing records 181 - 200 ( 303 total )
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Positive TC-PTH/HP Topline Eliminates SoC, Further Validates TransCon Platform
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
4Q/FY19, Timelines Unaffected by COVID-19 and TC-PTH Ph2 Topline Mid-April
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Q4/FY19, Timelines Unaffected by COVID-19 and TC-PTH Ph2 Topline Mid-April
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Emerging Pharma: Upcoming Material Catalysts in Companies with Plenty of Cash
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Corporate Update and TransCon PTH Ph2 Topline Results End of March
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
PaTH Forward for TransCon PTH Expands Study Enrollment; Topline Data in Q1:20
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Initiation of Phase 3 TC-hGH Clinical Study in China
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Somatrogon Ph3 Non-Inferior; Despite Competition We Remain Positive on TC-hGH
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Thoughts on Competitor Data; We Remain Positive on TC-hGH Outlook
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L